Why testosterone can run low after testicular cancer
Testosterone can fall after testicular cancer because treatment reduces the tissue that makes it. Surgery removes one testicle, and chemotherapy or radiation can injure the hormone-making cells in the one that remains. The National Cancer Institute notes that chemotherapy for testicular cancer is associated with a higher risk of both hypogonadism and metabolic syndrome.
The risk depends on what treatment you had. A 2016 meta-analysis in Andrology compared survivors with men treated by orchiectomy alone and found higher odds of testosterone deficiency after each added treatment:
| Treatment beyond orchiectomy | Odds of testosterone deficiency vs orchiectomy alone |
|---|---|
| Standard chemotherapy | 1.8 times |
| Infradiaphragmatic radiotherapy | 1.6 times |
| Non-conventional or intensified therapy | 3.1 times |
MedlinePlus lists damage to the testicles from radiation or chemotherapy among the causes of a high LH, the signal the pituitary raises when the testes fall behind. That makes post-cancer low testosterone a form of primary hypogonadism.
Signs to watch for
The signs are the same as any low testosterone, which is why survivors sometimes put them down to stress or recovery. Common ones include lower sex drive, fewer morning erections, fatigue that lingers long after treatment, loss of muscle, weight gain around the middle, low mood and poorer concentration.
Some men sit in a middle zone: testosterone still in range, but LH high because the remaining testicle is working harder to keep up. That pattern, often called compensated, does not usually need treatment on its own. It is a reason to keep testing on a schedule, because some men drift lower over the years.
Weight gain, rising blood pressure and changing blood sugar or cholesterol are worth noticing too. The metabolic link the NCI describes is one reason survivors benefit from regular general checkups, covered on our page on metabolic syndrome in men.
How it is evaluated
The evaluation looks like any low testosterone workup, timed around your cancer care. The AUA guideline suggests measuring testosterone in men with past chemotherapy or testicular radiation even without symptoms, and it requires two early-morning measurements before diagnosing low testosterone.
The core tests are:
- two early-morning total testosterone draws
- LH and FSH, to confirm the testicular pattern; see our LH blood test page
- a complete blood count and PSA when therapy is being considered
- metabolic markers such as glucose and lipids, given the higher metabolic risk
Results are read with your treatment dates in mind, since levels right after chemotherapy may still be recovering.
Men who have lost both testicles, whether from cancer on both sides or surgery for precancerous changes, are in a different position. With no testicular tissue left, the body makes almost no testosterone, so replacement is needed for life. For them the question is not whether to treat but how, and how to fit monitoring around ongoing surveillance.
Coordinating with your oncologist
Care for survivors goes more smoothly when the hormone plan and the cancer surveillance plan are built together. Three things make that coordination essential.
Tumor markers. The NCI explains that AFP, beta-hCG and LDH are used to monitor germ cell tumors and that rising markers are often the earliest sign of relapse. It also notes that a high LH can cross-react with some beta-hCG tests and cause a false-positive result. Men with low testosterone after treatment often have a high LH, so your oncologist needs to know your hormone status when reading those markers. HCG treatment would directly raise beta-hCG, so it is generally not used without the oncology team’s agreement.
Fertility. The NCI notes that men can be offered sperm banking before any treatment other than orchiectomy, because chemotherapy, lymph node surgery and radiation can each cause infertility. Testosterone therapy suppresses sperm production further. If children are in your plans, read our page for men trying to conceive before starting anything.
The remaining testicle. The NCI reports roughly a 2 percent cumulative risk of cancer in the opposite testicle over the 15 years after diagnosis. Regular self-exams and reporting any change quickly stay important on testosterone therapy. MedlinePlus describes a painless lump or swelling as a common first sign.
Unlike prostate cancer, testicular germ cell cancer is not managed by lowering testosterone, so a history of it does not by itself rule out testosterone therapy. Our answer on TRT after testicular cancer covers the timing questions men ask most.
What TRT monitoring looks like for survivors
When low testosterone is confirmed and your oncology team agrees, monitoring follows the usual TRT schedule with a few survivor-specific additions.
| What is checked | Why |
|---|---|
| Testosterone level | Confirms the dose is in range |
| Hematocrit and blood count | Testosterone can raise red cell counts |
| PSA in men over 40 | Standard prostate safety check |
| Blood pressure, glucose, lipids, weight | Metabolic risk is higher after chemotherapy |
| Remaining testicle | Self-exams plus exam at visits |
| Oncology surveillance results | Shared so markers and imaging are read in context |
Your provider sets the testing schedule; our page on how often blood work is needed on TRT describes a typical first year.
When it is urgent
Some symptoms should go straight to your oncology team or an emergency room rather than waiting for a hormone visit. Contact your oncologist promptly about a new lump, swelling or heaviness in the remaining testicle, or new back pain, cough or breathlessness. Go to the ER for sudden severe testicular pain. Call 911 for chest pain, sudden shortness of breath or signs of a stroke.
How Ultimate Male works with your cancer team
We treat survivors’ hormone care as part of a shared plan, not a separate track. On the free 10-minute call, tell us what treatment you had, when it ended and who manages your surveillance.
At San Gabriel or Downey, morning blood is drawn on site and results come back in 24 to 48 hours. In a one-on-one visit, a PA-C or MD reviews your testosterone, LH and FSH against your treatment history and, with your permission, shares results with your oncologist. If testosterone therapy makes sense and your cancer team agrees, we set a monitoring schedule that fits around your surveillance visits. Our guide to coordinating care with your primary care doctor shows how we keep everyone informed.
